0001209191-15-002172.txt : 20150106 0001209191-15-002172.hdr.sgml : 20150106 20150106161745 ACCESSION NUMBER: 0001209191-15-002172 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150102 FILED AS OF DATE: 20150106 DATE AS OF CHANGE: 20150106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CELGENE CORP /DE/ CENTRAL INDEX KEY: 0000816284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222711928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: (908)673-9000 MAIL ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAPLAN GILLA CENTRAL INDEX KEY: 0001247024 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34912 FILM NUMBER: 15510233 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 FORMER NAME: FORMER CONFORMED NAME: KAPLAN GILLA PHD DATE OF NAME CHANGE: 20030625 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-01-02 0 0000816284 CELGENE CORP /DE/ CELG 0001247024 KAPLAN GILLA C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 1 0 0 0 Common Stock 79508 D Common Stock 2015-01-02 4 M 0 45536 16.2125 A 45536 I By family trust Common Stock 2015-01-02 4 S 0 45536 113.4736 D 0 I By family trust Stock Option (right to buy) 16.2125 2015-01-02 4 M 0 45536 0.00 D 2015-12-29 Common Stock 45536 0 I By family trust The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. These shares were sold by two family trusts (the trustee of which is Dr. Kaplan's brother-in-law and the beneficiaries of which are Dr. Kaplan's immediate family members) pursuant to Rule 10b5-1 plans in multiple transactions at prices ranging from $112.65 to $114.35, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. The option was fully exercisable. The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan. /s/Robert J Hugin______________________ Robert J Hugin, Attorney-in-Fact 2015-01-06